---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-006081"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:16:29.150961+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bioxytran reports Phase 2 ProLectin-M shows 100% viral clearance at day 7; p=0.001

## Summary
- 100% of treated subjects achieved complete viral clearance by Day 7 vs placebo (p=.001).
- No viral rebounds observed during the 14-day post-treatment observation period.
- 16 of 38 subjects had non-detection by Day 5; 1 of 38 by Day 3.
- Phase 2 dose-optimization trial: randomized, double-blind, 38 subjects completed.
- Company plans regulatory discussions for late-stage development and additional viral indications.

## SEC filing metadata
- accession: 0001493152-26-006081
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315226006081/0001493152-26-006081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315226006081/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-006081
- JSON: https://secwatch.observer/filing/0001493152-26-006081.json
- Plain text: https://secwatch.observer/filing/0001493152-26-006081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.